<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964493</url>
  </required_header>
  <id_info>
    <org_study_id>PJI001-02</org_study_id>
    <nct_id>NCT03964493</nct_id>
  </id_info>
  <brief_title>TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection</brief_title>
  <acronym>P2_ABSSSI</acronym>
  <official_title>Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TenNor Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TenNor Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetic
      characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be
      caused by gram-positive pathogens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2, double-blind, randomized, multicenter, parallel, controlled study is conducted
      to evaluate safety, tolerability, pharmacokinetics and efficacy of TNP-2092, and vancomycin
      in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens. The
      duration of the treatment period is a minimum of 7 days and a maximum of 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TNP-2092 300 mg intravenous every 12 hours vancomycin 1 g intravenous every 12 hours</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events as assessed by CTCAE v4.0</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Incidence, causality, and severity
thrombotic events
local infusion site reactions
tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination-Weight</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Weight in kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination-Hight</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Hight in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination- others</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>head, ears, eyes, nose, throat dentition, thyroid, chest(heart, lungs),abdomen, skin/soft tissues, neurological, extremities, back, neck, musculoskeletal, and lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs-Temperature</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Oral Temperature in celsius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs- pulse rate</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs- respiratory rate</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs - blood pressure</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>blood pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major serum chemistry findings - ALT</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>ALT in IU/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major serum chemistry findings - AST</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>AST in IU/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major serum chemistry findings - Billirubin</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Billirubin in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major hematology findings - WBC</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>WBC in K/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major hematology findings - RBC</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>RBC in K/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major hematology findings - Platelet</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Platelet in K/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major coagulation findings - PT</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>PT (protime) in seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major coagulation findings - PTT</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>PTT (partial thromboplastin time) in seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major urinalysis findings -pH</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>pH value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major urinalysis findings - Glucose</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Glucose in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major urinalysis findings - Protein</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Protein in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heptoglobin</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Heptoglobin in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG findings</measure>
    <time_frame>Day 1 to Day 40</time_frame>
    <description>Triplicate 12-lead ECG assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary PK parameters-Cmax</measure>
    <time_frame>The first dose (Day 1) and the last dose (Day 3-14)</time_frame>
    <description>Peak Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary PK parameters-tmax</measure>
    <time_frame>The first dose (Day 1) and the last dose (Day 3-14)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary PK parameters - AUC0-12</measure>
    <time_frame>The first dose (Day 1) and the last dose (Day 3-14)</time_frame>
    <description>AUC versus time from time 0 to 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmatic clinical response</measure>
    <time_frame>EA (48-72 hour) and EOT (Day 7-14)</time_frame>
    <description>Percent reduction in primary ABSSSI lesion size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response</measure>
    <time_frame>EA (48-72 hour) and EOT (Day 7-14)</time_frame>
    <description>Bacteria identification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's assessment</measure>
    <time_frame>EA (48-72 hour) and EOT (Day 7-14)</time_frame>
    <description>Improvement, Failure or Indeterminate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Skin and Subcutaneous Tissue Bacterial Infections</condition>
  <condition>Gram-Positive Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>TNP-2092</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNP-2092 300 mg intravenous every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vancomycin 1 g intravenous every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNP-2092</intervention_name>
    <description>TNP-2092 100mg/vial</description>
    <arm_group_label>TNP-2092</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 1g/vial</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects may be included in the study if they meet all of the following inclusion
             criteria:

               -  Males or females, 18 years of age or older;

               -  ABSSSI suspected or confirmed to be caused by gram-positive pathogens, including:

               -  Cellulitis/erysipelas;

               -  Wound infection;

               -  Major cutaneous abscess;

               -  Lesion with a minimum surface area of 75 cm2;

               -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if any of the following exclusion criteria
             apply prior to randomization:

               -  History or hypersensitivity or intolerability to any fluoroquinolone, rifamycin
                  or glycopeptide classes;

               -  ABSSSI suspected or confirmed to be caused by pathogens that are resistant to the
                  glycopeptide class;

               -  Prior administration of systemic antibacterial therapy within 96 hours before
                  randomization;

               -  ABSSSI with suspected or confirmed infection caused by gram-negative or anaerobic
                  organisms;

               -  ABSSSI with suspected or confirmed infection caused by fungal, mycobacterial,
                  parasitic, or viral pathogens;

               -  Evidence of significant hepatic, hematologic, or immunologic disease;

               -  History or evidence of severe renal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TenNor</last_name>
    <phone>+86-512-86861990</phone>
    <email>info@tennorx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Overcash, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNP-2092</keyword>
  <keyword>ABSSSI</keyword>
  <keyword>Safety</keyword>
  <keyword>PK</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

